TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: KN046 in Subjects With Advanced Solid Tumors and Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent; willing and able to complete all required procedures of study.~2. With advanced-stage or metastatic tumor (unresectable) and experienced progression since last anti-tumor treatment; standard therapy is not available or rejected.~3. Subjects must have at least one measurable lesion in advanced solid tumors, at least one measurable or assessable lesion in NK/T cell lymphoma.~4. ECOG performance status of 0 or 1.~5. Subject must have adequate organ function.~6. Female patients and males with partners of childbearing potential should be using highly effective contraceptive measures (failure rate of less than 1% per year). Contraception should be continued for a period of 24 weeks after dosing has been completed.~7. Ability to comply with treatment, procedures and PK sample collection and the required study follow-up procedures.~Exclusion Criteria:~1. Known brain metastasis or other CNS metastasis that is either symptomatic or untreated.~2. Is currently participating or has participated in a study of an investigational drug within 4 weeks prior to the first dose of trial treatment.~3. Patients who have received immune checkpoint proteins/antibody/medicine (including PD-1, PD-L1, etc) for treatment.~4. Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.~5. Subjects with active autoimmune diseases or history of autoimmune diseases should be excluded.~6. Active HBV or HCV infection.~7. Known HIV infection or known history of acquired immune deficient syndrome (AIDS).~8. Any unresolved CTCAE Grade ≥ 2 toxicities from prior anti-cancer therapy with the exception of vitiligo, alopecia.~9. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KN046 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: d13C Added Sugar Intake Biomarker: Determining Validity in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cross-sectional study: Age 6-18, both genders~* Controlled feeding study: Age 12-18, both genders, BMI \<95%ile~Exclusion Criteria:~* Controlled feeding study: Food allergies and/or aversions, BMI\>95%ile

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Low, then high added sugar diet (Type: EXPERIMENTAL): Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
- High, then low added sugar diet (Type: EXPERIMENTAL): Participants will consume a high added sugar (25% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a low added sugar (5% total energy) diet for 7 consecutive days
- Dietary recall and fingerstick (Type: NO_INTERVENTION): Participants will complete 4 in-person 24-hr dietary recalls and 2 fingerstick blood samples at Visit 1 and 3 within 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histologically documented diagnosis of invasive breast cancer that is locally advanced or metastatic~* Previous anthracycline containing chemotherapy~* Presence of a certain protein on the cell surface (c-kit (CD117) and /or PDGF-receptor)~* Preferably tumor samples should be taken within 6 weeks of study entry. Most recent primary tumor tissue has to be available for analysis~* Acceptable health status (Eastern Cooperative Oncology Group \[ECOG\]-performance status 0,1, 2 or 3)~Exclusion criteria: (for the second-line therapy)~* Patient with Grade III/IV cardiac problems (i.e., congestive heart failure, myocardial infarction within 6 months of study) and with severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).~* Patient has a known brain metastasis, chronic liver disease (i.e., chronic active hepatitis, and cirrhosis) and diagnosis of (HIV) infection.~* Patient received chemotherapy within 4 weeks prior to study entry, unless the disease is rapidly progressing.~* Patient previously received radiotherapy to ≥ 25 % of the bone marrow and had a major surgery within 2 weeks prior to study entry.~* Patient received either Vinorelbine or Imatinib in previous treatment regimens~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib + Vinorelbine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 12 years of age or older.~* Has a diagnosis of facial acne vulgaris with no more than two nodules on the face.~Exclusion Criteria:~* Is allergic to tetracycline-class antibiotics or to any ingredient in the study medication.~* Has a history of pseudomembranous colitis or antibiotic-associated colitis.~* Has a history of hepatitis or liver damage or renal impairment.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxycycline hyclate (Doryx) (Type: EXPERIMENTAL): None
- Doxycycline hyclate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥18 years old~* Diagnosed with type 2 diabetes~* Body mass index (BMI) ≤ 45 kg/m2~* HbA1c between 7 and 10% (inclusive) at screening~* FPG \<250 mg/dL at screening for subjects not treated with oral anti-diabetic therapies or FPG \<240 mg/dL at screening for subjects treated with anti-diabetic therapies~* Diabetes currently treated with diet and exercise only or diet and exercise along with one approved oral anti-diabetic agent~* If taking anti-diabetic medication, dose and regimen must be stable for past 3 months~* If taking anti-hypertensive medication, dose and regimen must be stable for past 3 months~* If taking lipid modifying therapy, dose and regimen must be stable for past 3 months~* Blood glucose \<250 mg/dL based on finger stick blood glucose for all subjects at randomization~Exclusion Criteria:~* Hemoglobinopathy that affects HbA1c measurement~* Current use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor based therapy)~* Genitourinary tract infection within 6 weeks of screening~* Greater than 2 episodes of genitourinary tract infection in the past year~* History of kidney stones, bladder malfunction or other significant risk factor for urinary tract infections~* eGFR, as calculated by the modification of diet in renal disease study equation (MDRD), \< 50 mL/min/1.73 m2~* Abnormal tests of liver function ALT, AST or bilirubin ≥ 3x ULN~* Diagnosis of retinopathy or significant nephropathy (eGFR \< 50 mL/min/1.73 m2~* Uncontrolled hypertension (systolic blood pressure \>160 or diastolic blood pressure \>95)~* Not willing to use effective birth control, if female with child-bearing potential~* Life expectancy \< 2 years~* New York Heart Association (NYHA) Class 4 heart failure~* Sera positive of HCV, HIV, or positive on drug screen~* Currently participating in another interventional trial~* Previous treatment with EGT0001442 or EGT0001474~* Not able to comply with the study scheduled visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- EGT0001442 (Type: EXPERIMENTAL): EGT0001442 capsule, 20 mg, daily, 96 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Meet all inclusion criteria for the AIBL study protocol, with amyloid PET conducted or planned and MRI available~* Subjects in the MCI and AD groups required to have a reliable caregiver capable of providing information about the subjects' symptoms~Exclusion Criteria:~* lifetime history of schizophrenia, schizoaffective disorder, or bipolar disorder~* history of electroconvulsive therapy~* MRI contraindicated~* claustrophobic or, otherwise, unable to tolerate the imaging procedure~* current clinically significant cardiovascular disease or clinically significant abnormalities on screening electrocardiogram~* history of additional risk factors for Torsades de Pointes~* current clinically significant infectious disease, endocrine or metabolic disease, or pulmonary, renal, or hepatic impairment that the investigator believes would affect study participation~* history of cancer (other than skin or in situ prostate cancer) within the previous 5 years~* current drug or alcohol abuse/dependence~* history of alcohol abuse/dependence with 2 years of the onset of the symptoms of dementia~* females of childbearing potential who were not surgically sterile, not refraining from sexual activity, or not using reliable methods of contraception

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Alzheimer's disease (AD) (Type: EXPERIMENTAL): Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months
- Mild cognitive impairment (MCI) (Type: EXPERIMENTAL): Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months
- Subjective memory complainers (SMC) (Type: EXPERIMENTAL): Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months
- Cognitively normal (CN) (Type: EXPERIMENTAL): Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Relapsing-remitting MS (RRMS) or secondary-progressive MS (SPMS)~* Previous treatment with disease modifying drugs~* Adjustment of disease modifying treatment necessary at the discretion of the investigator~* Switch to Betaferon at least 1 month but not longer than 3 months prior to inclusion~Exclusion Criteria:~* Patients not fulfilling the indications in the local prescribing information~* Refusal to sign inform consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Controlled Clinical Trial on The Use of a Specific Antivenom Against Envenoming by Bungarus Multicinctus

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Envenomed by B. multicinctus~* Showed clinical signs of systemic envenomation (neuromuscular signs)~* Provided written informed consent (during the year 2006)~Exclusion Criteria:~* Pregnancy~* Patients had a known history of intolerance to equine serum

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control group (Type: OTHER): As the antivenom was not yet clinically available until 2006, all patients included during the first two years (2004-2005) received supportive therapy only.
- antivenom group (Type: ACTIVE_COMPARATOR): The patients included during the third year (2006) were treated with antivenom therapy and supportive care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Is 8 to 17 years of age, inclusive, at the time of randomization/initiation of study drug administration.~2. Has received a diagnosis of type 1 diabetes (T1D) according to the criteria from the American Diabetes Association.~3. Is able to be randomized and initiate study drug within 6 weeks (42 days) of the formal T1D diagnosis.~4. Has a peak stimulated C-peptide of ≥0.2 pmol/mL from a mixed meal tolerance test (MMTT) at screening.~5. Has a positive result on testing for T1D-related autoantibodies.~Exclusion Criteria:~1. Has any autoimmune disease other than T1D with the exception of stable thyroid or celiac disease.~2. Has an active infection and/or fever.~3. Has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).~4. An individual who has a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Teplizumab (Type: EXPERIMENTAL): Teplizumab was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days.~Each course included:~* Day 1: 106 μg/m\^2~* Day 2: 425 μg/m\^2~* Days 3-12: 850 μg/m\^2 Total per course: 9.0 mg/m\^2 The doses of study drug were calculated based on the participant's body surface area (BSA) measured on the first day of each treatment course.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days.~The placebo solution consisted of the same formulation as the study drug but without teplizumab. Placebo was administered in the same dose volume and by the same treatment schedule as the active drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 90 years of age inclusive~* Female patients can participate if they are surgically sterile or completed menopause or females capable of having children and agree not to attempt pregnancy while receiving IV study therapy and for a period of 7 days after~* Has pyuria with \>/= 10 WBCs (white blood cell) and has a positive urine culture within 48 hours of enrollment containing \>/=10 to the fifth CFU (colony forming unit ) /ml of a recognized uropathogen known to be susceptible to IV study therapy (CAZ-AVI and doripenem)~* Demonstrates either acute pyelonephritis or complicated lower UTI without pyelonephritis~Exclusion Criteria:~* Urine pathogen is a Gram-positive pathogen or a uropathogen resistant to CAZ-AVI or doripenem~* Patient's urine culture at study entry isolates more than 2 microorganisms regardless of colony count or patient has a confirmed fungal UTI~* Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant~* Patient is immunocompromised~* Patient is considered unlikely to survive the 6- to 8-week study period or has a rapidly progressive or terminal illness including septic shock which is associated with a high risk of mortality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ceftazidime - Avibactam ( CAZ-AVI) (Type: EXPERIMENTAL): IV treatment
- Doripenem (Type: ACTIVE_COMPARATOR): IV treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Electrical Impedance Tomography for Optimization of Positive End-Expiratory Pressure: Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Endotracheal ventilation for \< 1 week (168 hours)~* Presence of all of the following conditions for \< 48 hours i. Partial pressure of oxygen to percentage of inspired oxygen (PaO2/FiO2) \< 150 with PEEP \> 5 cm water for \> 30 min.~ii. bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules iii. respiratory failure not fully explained by cardiac failure or fluid overload~-All criteria listed in (3) developed within 1 week of a known clinical insult or new or worsening respiratory symptoms~Exclusion Criteria:~* Lack of informed consent~* Known pregnancy~* Extracorporeal membrane oxygenation (ECMO) use~* Severe chronic respiratory disease requiring home oxygen therapy or ventilation~* Calculated BMI of greater than 50

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual care then PEEP titration by Electrical Impedance Tomography (EIT) (Type: EXPERIMENTAL): Patients in the usual care first group will continue to receive mechanical ventilation according to the University of Michigan Acute Respiratory Distress Syndrome (ARDS) protocol high-PEEP arm
- PEEP titration by EIT then usual care (Type: EXPERIMENTAL): Patients in the high PEEP titration by EIT first will have receive ventilation with a PEEP determined by EIT titration procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to give consent~* Women of childbearing potential must have a) negative urine pregnancy test b) not be breast feeding c) agree to practice a reliable form of contraception~* Diagnosis of cancer~* Taking at least 60mg oral morphine or equivalent as 24 hour treatment for cancer-related pain~* Experiencing on average 1 - 4 episodes of breakthrough cancer pain per day usually controlled by rescue pain medication~* Able (or via caregiver) to evaluate and record pain relief, assess medication performance at set times after dosing, record adverse events, record each use of the study drug or rescue medication in a diary~* Able to be up and about for 50% of the day or greater~Exclusion Criteria:~* Intolerance to opioids or fentanyl~* rapidly increasing/uncontrolled pain~* pain that is not cancer related

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fentanyl, Open-Label treatment (Type: EXPERIMENTAL): All patients take NasalFent at effective dose to treat up to four episodes of breakthrough cancer pain per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete